ReviewFrontiers in immunology2021
Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review.Current cancer drug targets · 2025Pooled it
- Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Polysaccharides: Natural candidates for targeting immunometabolic regulation in hepatocellular carcinoma (Review).Molecular medicine reports · 2026Review
- Survival and Tumour Microenvironment in Spatially Distinct Regions in Patients Resected for Hepatocellular Carcinoma: A Multicentre Study.Journal of gastrointestinal cancer · 2026Article
- Therapeutic Strategies for Hepatocellular Carcinoma: Current Advances and Future Perspectives.Vaccines · 2026Review
- HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications.Clinical and experimental medicine · 2026Review
- Neutrophil Senescence Induced by Tumor-Derived HMGB1 Promotes Hepatocellular Carcinoma Progression through Neutrophil Extracellular Trap-Mediated Suppression of CD8Cancer communications (London, England) · 2026Article
- TMEM106C, BSG, COPE, CDCA8, KPNA2, LIG1, UQCRH, and CCT5: Predictive of Survival and Immunotherapy Resistance in Hepatocellular Carcinoma.Human mutation · 2026Article
- Associations between diffusion-weighted imaging and immunohistochemical features in hepatocellular carcinoma: a preliminary analysis of tumor-infiltrating lymphocytes and microvessel density expression.Clinical and experimental hepatology · 2025Article
- Exploration of signature-related FAM genes and correlation between FAM50A expression and the pathogenesis and prognosis of hepatocellular carcinoma.Translational cancer research · 2025Article
- T lymphocyte-based immune response and therapy in hepatocellular carcinoma: focus on TILs and CAR-T cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A Comparative Analysis of the Roles of von Willebrand Factor and ADAMTS13 in Hepatocellular Carcinoma: A Bioinformatics and Microarray-Based Study.Current issues in molecular biology · 2025Article
- SEPT9 and PAI-1 are immunohistochemical biomarkers of the hepatocellular carcinoma immune microenvironment.Discover oncology · 2025Article
- Controlling nutritional status score is a predictor of survival in hepatocellular carcinoma: A meta-analysis and meta-regression.Pakistan journal of medical sciences · 2025Review
- Identification of tumor immune infiltration-associated VPS72 and prognostic significance of VPS72 and CD8A in hepatocellular carcinoma.Discover oncology · 2025Article
- Prognostic relevance of sarcopenia and tumor-infiltrating CD8Annals of gastroenterological surgery · 2025Article
- PAXIP1 is regulated by NRF1 and is a prognosis‑related biomarker in hepatocellular carcinoma.Biomedical reports · 2025Article
- HBV-associated hepatocellular carcinomas inhibit antitumor CD8Nature communications · 2025Article
- Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy.World journal of gastrointestinal surgery · 2025Article
- Clinical significance of the Naples prognostic score in predicting short- and long-term postoperative outcomes of patients with hepatocellular carcinoma.World journal of surgery · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer (PLC) is one of the most common malignancies in China, where it ranks second in mortality and fifth in morbidity. Currently, liver transplantation, hepatic tumor resection, radiofrequency ablation, and molecular-targeted agents are the major treatments for hepatocellular carcinoma (HCC). Overall, HCC has a poor survival rate and a high recurrence rate. Tumor-infiltrating lymphocytes (TILs) have been discovered to play essential roles in the development, prognosis, and immunotherapy treatment of HCC. As the major component cells of TILs, T cells are also proved to show antitumor and protumor effects in HCC. Foxp3+, CD8+, CD3+, and CD4+ T lymphocytes are the broadly studied subgroups of TILs. This article reviews the roles and mechanisms of different tumor-infiltrating T lymphocyte subtypes in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.